FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

Thanks to two FDA nods, Eli Lilly’s Verzenio doesn’t need results from a biomarker test to treat certain patients with early breast cancer, and it can reach metastatic disease regardless of menopausal status.